Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$14.61 -2.2%	$14.42	$6.66 ▼ $17.15	$383.51M	0.44	43,016 shs	182,501 shs
CMPS COMPASS Pathways	$4.63 -3.5%	$4.09	$2.49 ▼ $8.54	$433.18M	2.25	929,812 shs	2.10 million shs
GALT Galectin Therapeutics	$2.42 -26.4%	$1.45	$0.73 ▼ $3.90	$153.16M	0.54	406,496 shs	4.32 million shs
OLMA Olema Pharmaceuticals	$4.13 +0.7%	$4.66	$2.86 ▼ $16.62	$282.58M	2	814,726 shs	1.03 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	0.00%	-11.35%	+10.77%	+1.88%	+112.35%
CMPS COMPASS Pathways	0.00%	+5.47%	+6.19%	+48.87%	-25.80%
GALT Galectin Therapeutics	0.00%	+76.64%	+89.06%	+46.67%	+3.42%
OLMA Olema Pharmaceuticals	0.00%	-0.96%	-18.06%	-4.40%	-64.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.5031 of 5 stars	3.6	2.0	2.9	2.5	0.0
CMPS COMPASS Pathways	1.7021 of 5 stars	3.5	3.0	0.0	0.8	0.6
GALT Galectin Therapeutics	1.6205 of 5 stars	3.5	0.0	3.1	1.7	0.0
OLMA Olema Pharmaceuticals	1.7585 of 5 stars	3.5	1.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.22	Buy	$23.83	63.13% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	306.77% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	147.93% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	493.22% Upside

Current Analyst Ratings Breakdown

Latest GALT, OLMA, BNTC, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/10/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$18.00 ➝ $20.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	4,793.91	N/A	N/A	$4.68 per share	3.12
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	N/A
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	8/12/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)

Latest GALT, OLMA, BNTC, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
GALT Galectin Therapeutics	N/A	0.08	0.08
OLMA Olema Pharmaceuticals	N/A	15.22	15.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
GALT Galectin Therapeutics	11.68%
OLMA Olema Pharmaceuticals	91.78%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
GALT Galectin Therapeutics	50.10%
OLMA Olema Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable

GALT, OLMA, BNTC, and CMPS Headlines

Recent News About These Companies

Q2 EPS Forecast for Olema Pharmaceuticals Cut by Analyst

June 4, 2025 | marketbeat.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Wellington Management Group LLP

June 3, 2025 | marketbeat.com

H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance

May 30, 2025 | msn.com

Olema Pharmaceuticals Selects 90 mg Palazestrant Dose for Phase 3 OPERA-01 and OPERA-02 Trials

May 29, 2025 | nasdaq.com

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Millennium Management LLC

May 29, 2025 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

May 29, 2025 | marketbeat.com

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 28, 2025 | globenewswire.com

BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

May 23, 2025 | marketbeat.com

Olema Oncology to Participate in Upcoming Investor Conferences

May 21, 2025 | globenewswire.com

Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High?

May 21, 2025 | zacks.com

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

May 13, 2025 | globenewswire.com

What Role Might (NASDAQ:OLMA) Play in the Changing Landscape of the...

May 12, 2025 | kalkinemedia.com

Olema Oncology to Participate in Upcoming Investor Conferences

May 9, 2025 | globenewswire.com

Why Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.94%

May 6, 2025 | aaii.com

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2025 | globenewswire.com

H.C. Wainwright Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

April 30, 2025 | theglobeandmail.com

Why Olema Pharmaceuticals, Inc.’s (OLMA) Stock Is Down 5.78%

April 25, 2025 | aaii.com

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

April 25, 2025 | globenewswire.com

Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet

April 24, 2025 | zacks.com

After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)

April 10, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, OLMA, BNTC, and CMPS Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$14.61 -0.33 (-2.21%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.56 -0.05 (-0.38%)

As of 06/20/2025 04:11 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.63 -0.17 (-3.54%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.59 -0.04 (-0.86%)

As of 06/20/2025 07:47 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Galectin Therapeutics NASDAQ:GALT

$2.42 -0.87 (-26.44%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.41 -0.01 (-0.41%)

As of 06/20/2025 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Olema Pharmaceuticals NASDAQ:OLMA

$4.13 +0.03 (+0.73%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.14 +0.00 (+0.12%)

As of 06/20/2025 07:57 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time